Treatment -Resistant Neovascular Age-Related Macular Degeneration

NCT02332941 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: Rituximab

Sponsor

Washington University School of Medicine